- 22 Jun 2020 Kymab presents two e-posters at the American Association for Cancer Research Virtual Annual Meeting
- 3 Jun 2020 US Patent Trial and Appeal Board rejects fifth request by Regeneron for invalidation of Kymab's US patents
- 6 Dec 2019 Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition
- 13 Nov 2019 Kymab to Present Update on Lead Immunocytokine Program KY1043 at Two European Scientific Meetings in November 2019
- 8 Nov 2019 Kymab Presents Update on Lead Immunocytokine Program KY1043 at Society of Immunotherapy for Cancer 34th Annual Meeting
- 3 Oct 2019 Kymab Announces Presentation on KY1049 at the European Congress on Thrombosis and Haemostasis
- 27 Sep 2019 Kymab outlines positive new findings for its KY1044 Anti-ICOS program at the CICON 2019 Annual Meeting
- 24 Jun 2019 Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies
- 13 Jun 2019 Kymab Announces Presentations at the 24th EHA Annual Congress
- 1 Jun 2019 Kymab Poster on Adaptive Phase 1/2 Clinical Trial for KY1044 anti-ICOS Program at 2019 ASCO Meeting
We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Featured article: Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium
Potent antibody drug combinations identified
Read article
Featured article: Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis
Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases a...
Read article
Featured article: Kymab wins Supreme Court case against Regeneron
Landmark UK Supreme Court decision invalidates Regeneron Patent claims
Read article